TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Large-scale batteries are integral in shift to renewable energy
  2. Plastics, tech sectors crucial to cracker plants
  3. Energy Spotlight: Steve Anthos
  4. Hackers rip into heart of open-source software
  5. Open enrollment puts varied impact of health care law back in focus
  6. Student loan debt presents paradox
  7. Duquesne University business center helping Hispanic startups
  8. Universal theme park swings into Beijing
  9. Mortgage in reach despite few dings
  10. BNY Mellon profits up in third quarter
  11. Without pipelines, gas can’t get to demand
Subscribe today! Click here for our subscription offers.